Hospital
ST Vincent Charity Medical Center
ST Vincent Charity Medical Center was paid $22.32M by Medicaid between Jan 2018 and Nov 2022, across 165 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoST VINCENT CHARITY MEDICAL CENTER
CLEVELAND, OH 44115
CLEVELAND, OH 44115
33aNPI1710951801assigned 02/15/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.32M
24GClaims442,354
24DCodes billed165
24AFirst – last monthJan 2018 – Nov 2022
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#51 of 101
Median peer was paid$22.32M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 96,556 | $3.01M | |
| 2019 | 99,945 | $3.16M | |
| 2020 | 83,852 | $5.95M | |
| 2021 | 94,800 | $5.90M | |
| 2022 | 67,201 | $4.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 50,902 | 48,579 | $8.19M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 21,906 | 20,875 | $3.76M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.7% | 22,658 | 18,688 | $2.16M |
| H0012 | Alcohol and/or drug services; sub-acute detoxification (residential addiction program outpatient) | 5.7% | 3,240 | 969 | $1.27M |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 5.7% | 9,930 | 1,259 | $1.26M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 2.4% | 6,357 | 5,977 | $536K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.0% | 20,973 | 14,930 | $446K |
| 80053 | Comprehensive metabolic panel | 1.9% | 29,717 | 26,868 | $419K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 1.6% | 6,090 | 2,089 | $356K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.5% | 1,842 | 1,725 | $338K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.4% | 5,306 | 5,138 | $314K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 511 | 480 | $292K |
153 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 11,462 | $285K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,693 | $281K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 1,302 | $250K |
| 80320 | <1% | 10,044 | $183K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,137 | $154K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,503 | $107K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 796 | $92K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 318 | $81K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,145 | $69K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,314 | $66K |
| 80061 | Lipid panel | <1% | 4,428 | $63K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,867 | $62K |
| 36415 | Collection of venous blood by venipuncture | <1% | 45,719 | $60K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,732 | $60K |
| 73630 | <1% | 922 | $59K | |
| 90837 | Psychotherapy session, about an hour | <1% | 613 | $56K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,246 | $52K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,056 | $50K |
| G0378 | Hospital observation service, per hour | <1% | 1,115 | $47K |
| 82607 | <1% | 1,261 | $44K | |
| 11721 | <1% | 904 | $40K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 224 | $37K |
| 84484 | <1% | 4,714 | $36K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,290 | $35K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 3,267 | $34K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 155 | $32K |
| 85027 | <1% | 2,993 | $30K | |
| 86481 | <1% | 251 | $29K | |
| 80076 | <1% | 1,535 | $24K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 276 | $24K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 219 | $22K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 417 | $22K |
| 85060 | <1% | 2,321 | $21K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 189 | $21K |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 1,021 | $20K |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 564 | $20K |
| 83540 | <1% | 1,115 | $20K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 113 | $20K |
| 82570 | <1% | 1,294 | $20K | |
| 88307 | <1% | 434 | $19K | |
| 83550 | <1% | 1,111 | $17K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 40 | $17K |
| 11056 | <1% | 49 | $15K | |
| 86803 | <1% | 198 | $13K | |
| 98940 | <1% | 275 | $13K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,025 | $12K |
| 82728 | <1% | 337 | $12K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 39 | $12K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 27 | $11K |
| 84450 | <1% | 419 | $9K | |
| 87340 | <1% | 213 | $9K | |
| 83735 | <1% | 1,175 | $9K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,530 | $9K |
| 82043 | <1% | 745 | $8K | |
| 85610 | <1% | 1,188 | $8K | |
| 97810 | <1% | 162 | $8K | |
| 80349 | <1% | 538 | $7K | |
| 93017 | <1% | 160 | $7K | |
| 82075 | <1% | 273 | $6K | |
| 86677 | <1% | 263 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,953 | $6K |
| 84460 | <1% | 419 | $6K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 203 | $6K |
| 88304 | <1% | 787 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 139 | $5K |
| 81025 | <1% | 11,694 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,640 | $5K |
| 88311 | <1% | 680 | $5K | |
| 84436 | <1% | 421 | $4K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 278 | $4K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 192 | $4K |
| 97811 | <1% | 162 | $4K | |
| 73610 | <1% | 49 | $3K | |
| 81001 | <1% | 11,659 | $3K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12 | $3K |
| 0002A | <1% | 101 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 329 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,075 | $3K |
| 0001A | <1% | 106 | $3K | |
| 73564 | <1% | 26 | $3K | |
| 80354 | <1% | 231 | $3K | |
| 86850 | <1% | 123 | $3K | |
| 84439 | <1% | 60 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 156 | $2K |
| 86900 | <1% | 136 | $2K | |
| 84479 | <1% | 351 | $2K | |
| 81003 | <1% | 4,609 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,152 | $2K |
| 80359 | <1% | 112 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 17 | $1K |
| 87071 | <1% | 414 | $1K | |
| 86140 | <1% | 76 | $1K | |
| 87073 | <1% | 53 | $1K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 44 | $1K |
| 82550 | <1% | 1,094 | $1K | |
| 72050 | <1% | 13 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 317 | $1K |
| 90714 | <1% | 49 | $1K | |
| 86901 | <1% | 136 | $1K | |
| 72110 | <1% | 25 | $869.83 | |
| 82248 | <1% | 38 | $728.12 | |
| 99406 | <1% | 19 | $695.70 | |
| 87660 | <1% | 50 | $635.72 | |
| 73562 | <1% | 12 | $569.71 | |
| 86780 | <1% | 27 | $548.14 | |
| 0031A | <1% | 20 | $497.51 | |
| 87510 | <1% | 36 | $492.14 | |
| 82948 | <1% | 743 | $375.36 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,572 | $361.46 |
| 85651 | <1% | 95 | $351.50 | |
| 85730 | <1% | 54 | $342.77 | |
| 90686 | <1% | 100 | $330.58 | |
| 84703 | <1% | 211 | $291.78 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 47 | $286.75 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 656 | $259.47 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,402 | $239.59 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 28 | $236.34 |
| 86762 | <1% | 27 | $214.98 | |
| 80069 | <1% | 14 | $198.12 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 34 | $175.69 |
| 80164 | <1% | 12 | $154.16 | |
| 87077 | <1% | 129 | $149.60 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 12 | $134.37 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,044 | $131.65 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,410 | $94.79 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 42 | $94.10 |
| 88300 | <1% | 38 | $83.10 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 18 | $81.61 |
| 84153 | <1% | 20 | $80.55 | |
| 85379 | <1% | 73 | $78.17 | |
| 83690 | <1% | 740 | $63.19 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 508 | $57.55 |
| 99153 | Mod sedat endo service >5yrs | <1% | 313 | $48.06 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,541 | $26.06 |
| 82150 | <1% | 176 | $22.96 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 25 | $21.12 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 220 | $17.24 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,705 | $12.43 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 61 | $10.98 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 114 | $9.48 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 12 | $8.49 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 388 | $0.97 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 254 | $0.90 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 225 | $0.89 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 98 | $0.45 |
| 99152 | 0% | 511 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 74 | $0.00 |
| 73030 | 0% | 30 | $0.00 | |
| 73130 | 0% | 26 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 27 | $0.00 |
| 87480 | 0% | 36 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 12 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUSNACZYK, JOHN (SENIOR VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Outreach Professional Services INC | Cleveland, OH | $3.11M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.